Bitcoin Atom (CURRENCY:BCA) traded down 9.5% against the U.S. dollar during the 24-hour period ending at 20:00 PM Eastern on June 28th. During the last seven days, Bitcoin Atom has traded 43.6% lower against the U.S. dollar. Bitcoin Atom has a market capitalization of $6.28 million and $18,812.00 worth of Bitcoin Atom was traded on exchanges in the last day. One Bitcoin Atom coin can now be bought for about $0.35 or 0.00005904 BTC on major cryptocurrency exchanges including Octaex, Exrates and Stocks.Exchange.
Here’s how similar cryptocurrencies have performed during the last day:
Get Bitcoin Atom alerts:
Qbao (QBT) traded down 3.7% against the dollar and now trades at $0.23 or 0.00003837 BTC. Bean Cash (BITB) traded 5.9% lower against the dollar and now trades at $0.0034 or 0.00000058 BTC. Measurable Data Token (MDT) traded down 3.9% against the dollar and now trades at $0.0182 or 0.00000310 BTC. Pascal Lite (PASL) traded down 6% against the dollar and now trades at $0.0222 or 0.00000378 BTC. X-Coin (XCO) traded 4.5% lower against the dollar and now trades at $0.0070 or 0.00000119 BTC. High Voltage (HVCO) traded down 5.8% against the dollar and now trades at $0.0463 or 0.00000787 BTC. Distributed Credit Chain (DCC) traded flat against the dollar and now trades at $0.0294 or 0.00000499 BTC. Cybereits (CRE) traded 0.2% lower against the dollar and now trades at $0.0216 or 0.00000367 BTC. Fonziecoin (FONZ) traded flat against the dollar and now trades at $0.0012 or 0.00000013 BTC. PrismChain (PRM) traded 4.1% lower against the dollar and now trades at $0.0008 or 0.00000013 BTC.
Bitcoin Atom Coin Profile
Hot High Tech Stocks To Invest In 2019: Luby's, Inc.(LUB)
- [By Lisa Levin]
Check out these big penny stock gainers and losers
Prothena Corporation plc (NASDAQ: PRTA) shares dipped 69 percent to $11.48 after a disappointing update relating to the company's treatment for AL amyloidosis. Prothena, a clinical-stage biopharmaceutical company that focuses on therapies in the neuroscience and orphan categories, said a Phase 2b study of its therapy called NEOD001 failed to achieve its primary or secondary endpoints. Prothena's Phase 2b study explored its NEOD001 therapy versus a placebo in previously-treated patients with AL amyloidosis and persistent cardiac dysfunction.
Gridsum Holding Inc. (NASDAQ: GSUM) fell 44.3 percent to $4.06. Gridsum reported suspension of audit report on financial statements.
Flotek Industries, Inc. (NYSE: FTK) shares declined 34.1 percent to $4.16 as the company issued weak revenue forecast for the first quarter.
Akorn, Inc. (NASDAQ: AKRX) dropped 32.3 percent to $13.35 after Fresenius terminated its merger deal with Akorn.
Chicago Bridge & Iron Company N.V. (NYSE: CBI) fell 31.2 percent to $13.44. Subsea 7 made an unsolicited bid to buy McDermott for $7 per share. However, the acquisition offer is contingent on McDermot terminating its pending merger with Chicago Bridge & Iron.
Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (NYSE: VLRS) dropped 18 percent to $5.76. Controladora Vuela recently reported first-quarter results that showed a loss for the quarter. Imperial Capital downgraded Controladora Vuela Compania de Aviacion from Outperform to In-Line.
Atossa Genetics Inc. (NASDAQ: ATOS) fell 18.2 percent to $2.8797 after declining 19.35 percent on Friday.
Alcoa Corporation (NYSE: AA) fell 12.3 percent to $52.63.
Luby's, Inc. (NYSE: LUB) shares declined 10.3 percent to $2.448 following Q2 results.
Aceto Corporation (NASDAQ: ACET) shares tumbled 10 percent to $2.26.
Pier 1 Imports, Inc. (NYSE: PIR) dipped 9.7 percent
- [By Joseph Griffin]
Main Street Capital (NYSE: MAIN) and Luby’s (NYSE:LUB) are both finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.
- [By Max Byerly]
Headlines about Luby’s (NYSE:LUB) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Luby’s earned a news impact score of 0.10 on Accern’s scale. Accern also gave news coverage about the restaurant operator an impact score of 47.2262144037183 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Hot High Tech Stocks To Invest In 2019: Invesco Trust for Investment Grade Municipals(VGM)
- [By Max Byerly]
Media headlines about Invesco Van Kmpn Trst Fr Invst Grd Mncpl (NYSE:VGM) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Invesco Van Kmpn Trst Fr Invst Grd Mncpl earned a news impact score of 0.19 on Accern’s scale. Accern also gave headlines about the investment management company an impact score of 46.4657191418091 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Hot High Tech Stocks To Invest In 2019: Stryker Corporation(SYK)
- [By Dan Caplinger]
Finally, shares of Boston Scientific sank 6%. The medical device maker had jumped earlier in the week on reports that it might receive a takeover bid from industry peer Stryker (NYSE:SYK). Yet today, Stryker denied that it had been in acquisition talks with Boston Scientific, throwing cold water on the idea. With the downward push, Boston Scientific is now back to where the stock started the week before the reports surfaced in the first place. Boston Scientific will now apparently have to make the most of its own opportunities in the medical device space — at least unless another potential buyer comes around.
- [By Stephan Byrd]
Get a free copy of the Zacks research report on Stryker (SYK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Steve Symington]
Boston Scientific stock rose 7.4% today after The Wall Street Journal reported(subscription required) that the medical device specialist has received a takeover bid from rival Stryker Corporation (NYSE:SYK). Shares of Stryker simultaneously declined more than 5% on the news.
- [By Max Byerly]
State of Tennessee Treasury Department trimmed its stake in shares of Stryker Co. (NYSE:SYK) by 13.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 101,919 shares of the medical technology company’s stock after selling 16,340 shares during the period. State of Tennessee Treasury Department’s holdings in Stryker were worth $16,401,000 at the end of the most recent reporting period.